Anderson David G, Carmona Sergio, Naidoo Kubendran, Coetzer Theresa L, Carr Jonathan, Rudnicki Dobrila D, Walker Ruth H, Margolis Russell L, Krause Amanda
Department of Neurology, The University of the Witwatersrand Donald Gordon Medical Center, Johannesburg, South Africa.
Division of Human Genetics, University of the Witwatersrand, Johannesburg, South Africa.
Tremor Other Hyperkinet Mov (N Y). 2017 Dec 5;7:512. doi: 10.7916/D81J9PDX. eCollection 2017.
Huntington's Disease-like 2 (HDL2) is classified as a neuroacanthocytosis; however, this remains unverified. We aim to determine if acanthocytes are present in HDL2 and whether acanthocytes can differentiate HDL2 from Huntington's disease (HD).
We prospectively compared 13 HD and 12 HDL2 cases against 21 unaffected controls in Johannesburg. Blood smears were prepared using international standards and reviewed by at least two blinded reviewers. An acanthocytosis rate of greater than 1.2% in the dry smear or greater than 3.7% in the wet smear was designated a priori as the threshold for clinical significance based on previously established standards. Flow cytometry was performed on all but four of the cases. Red cell membrane protein analysis was performed on all participants.
There were 12 HDL2, 13 HD, and 21 controls enrolled. None of the HD or HDL2 participants had defined acanthocytosis or other morphological abnormalities. None of the HD or HDL2 cases had evidence of an abnormal band 3.
Acanthocytosis was not identified in either HDL2 or HD in our patient population. Our results, based on the first prospective study of acanthocytes in HDL2 or HD, suggest that screening for acanthocytes will not help establish the diagnosis of HD or HDL2, nor differentiate between the two disorders and raises the question if HDL2 should be placed within the neuroacanthocytosis syndromes.
亨廷顿舞蹈症样2型(HDL2)被归类为神经棘红细胞增多症;然而,这一点仍未得到证实。我们旨在确定HDL2患者中是否存在棘红细胞,以及棘红细胞是否能将HDL2与亨廷顿舞蹈症(HD)区分开来。
我们在约翰内斯堡对13例HD患者、12例HDL2患者和21名未受影响的对照者进行了前瞻性比较。按照国际标准制备血涂片,并由至少两名不知情的审阅者进行检查。根据先前确定的标准,干涂片棘红细胞增多率大于1.2%或湿涂片大于3.7%被预先指定为具有临床意义的阈值。除4例患者外,对所有病例均进行了流式细胞术检测。对所有参与者进行了红细胞膜蛋白分析。
共纳入12例HDL2患者、13例HD患者和21名对照者。HD或HDL2参与者均未出现明确的棘红细胞增多或其他形态学异常。HD或HDL2病例均无异常带3的证据。
在我们的患者群体中,HDL2和HD患者均未发现棘红细胞增多。我们基于对HDL2或HD中棘红细胞的首次前瞻性研究结果表明,筛查棘红细胞无助于HD或HDL2的诊断,也无法区分这两种疾病,这就引发了HDL2是否应归入神经棘红细胞增多症综合征的问题。